Tetrahydrofolate Dehydrogenase
"Tetrahydrofolate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the oxidoreductase class that catalyzes the reaction 7,8-dihyrofolate and NADPH to yield 5,6,7,8-tetrahydrofolate and NADPH+, producing reduced folate for amino acid metabolism, purine ring synthesis, and the formation of deoxythymidine monophosphate. Methotrexate and other folic acid antagonists used as chemotherapeutic drugs act by inhibiting this enzyme. (Dorland, 27th ed) EC 1.5.1.3.
| Descriptor ID |
D013762
|
| MeSH Number(s) |
D08.811.682.662.825
|
| Concept/Terms |
Tetrahydrofolate Dehydrogenase- Tetrahydrofolate Dehydrogenase
- Dehydrogenase, Tetrahydrofolate
- Folic Acid Reductase
- Acid Reductase, Folic
- Reductase, Folic Acid
- Dihydrofolate Dehydrogenase
- Dehydrogenase, Dihydrofolate
- Dihydrofolate Reductase
- Reductase, Dihydrofolate
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydrofolate Dehydrogenase".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydrofolate Dehydrogenase".
This graph shows the total number of publications written about "Tetrahydrofolate Dehydrogenase" by people in this website by year, and whether "Tetrahydrofolate Dehydrogenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2017 | 5 | 0 | 5 |
| 2018 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Tetrahydrofolate Dehydrogenase" by people in Profiles.
-
Stable and reproducible transgene expression independent of proliferative or differentiated state using BAC TG-EMBED. Gene Ther. 2018 08; 25(5):376-391.
-
High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine. Pathog Glob Health. 2018 03; 112(2):86-92.
-
Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely. Bioorg Med Chem. 2017 12 15; 25(24):6467-6478.
-
Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. Sci Rep. 2017 08 07; 7(1):7389.
-
Defining the Structural Basis for Allosteric Product Release from E. coli Dihydrofolate Reductase Using NMR Relaxation Dispersion. J Am Chem Soc. 2017 08 16; 139(32):11233-11240.
-
Lausannevirus Encodes a Functional Dihydrofolate Reductase Susceptible to Proguanil. Antimicrob Agents Chemother. 2017 04; 61(4).
-
Low prevalence of DHFR and DHPS mutations in Pneumocystis jirovecii strains obtained from a German cohort. Infection. 2017 Jun; 45(3):341-347.
-
Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax. J Infect Dis. 2011 Jan 15; 203(2):207-10.
-
Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost. 1997 Jun; 77(6):1052-4.